Names
Asparaginase erwinia chrysanthemi (recombinant)- rywn Rylaze®Indications and usage
Rylaze® is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Side effects needing medical attention
The most common adverse reactions are abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, fever, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia.